Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 11, 2000, Pages 1133-1147

  Stephan, C ^a   Jung, K ^a   Lein, M ^a   Sinha, P ^a   Schnorr, D ^a   Loening, S A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; KALLIKREIN; KALLIKREIN 2; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; HUMAN; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW;

ALPHA 1-ANTICHYMOTRYPSIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SERINE PROTEINASE INHIBITORS; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033730301     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (210)

1. Cancer statistics 2000
2. The clinical usefulness of prostate specific antigen: Update 1994
3. Screening for prostatic carcinoma with prostate specific antigen
4. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
5. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
6. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen
7. Serum prostate specific antigen as pre-screening test for prostate cancer
8. Percent free prostate-specific antigen: The next frontier in prostate-specific antigen testing
9. A guide to the interpretation of serum prostate specific antigen levels
10. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
11. Nonprostatic sources of prostate-specific antigen
12. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast
13. Prostate-specific antigen: Its usefulness in clinical medicine
14. Prostate-specific antigen
15. Enhancin the specificity of prostate-specific antigen (PSA): An overview of PSA density, velocity and age-specific reference ranges
16. Prostate specific antigen: A decade of discovery: What we have learned and where we are going
17. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer
18. Role of PSA and its indices in determining the need for repeat prostate biopsies
19. Serum prostate specific antigen complexed to α 1-antichymotrypsin as an indicator of prostate cancer
20. Prostate-specific antigen in serum occurs predominantly in complex with α 1-antichymotrypsin
21. A complex between prostate-specific antigen and α 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
22. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen
23. Regulation of the enzymatic activity of prostate-specific antigen and its reactions with cellular protease inhibitors in prostate cancer
24. Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era
25. Multiple forms of prostate specific antigen and the influences of immunoassay design on their measurement in patient serum
26. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors
27. Characterization and immunological determination of the complex between prostate-specific antigen and α2-macroglobulin
28. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
29. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
30. Analytical performance and clinical validity of two free prostate-specific antigen assays compared
31. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age
32. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer
33. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen
34. Advantages of replacing the total PSA assay with the assay for PSA-α 1-antichymotrypsin complex for the screening and management of prostate cancer
35. α 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia
36. Cloning and characterization of the α 1-antichymotrypsin produced by human prostate tissue
37. Immunohistochemical finding of α-1-antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer
38. Immunohistochemical evaluation of proliferating cell nuclear antigen, prostate-specific antigen and α 1-antichymotrypsin in human prostate cancer
39. 1-anti-chymotrypsin
40. Prostate specific antigen role and function
41. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: Biochemical and diagnostic implications
42. 'BPSA,' a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia
43. III. Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium
44. Prostate specific antigen in benign prostatic hyperplasia: Purification and characterization
45. Prostate-specific antigen, clinical use and staging: An overview
46. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer
47. Complex formation between PSA isoenzymes and protease inhibitors
48. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum
49. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue
50. Serum free prostate specific antigen: Isoenzymes in benign hyperplasia and cancer of the prostate
51. Glycotyping of prostate specific antigen
52. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors
53. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia
54. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer
55. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA
56. Determination of the 'reflex range' and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system
57. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
58. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
59. Serum concentrations of prostate specific antigen and its complex with α 1-antichymotrypsin before diagnosis of prostate cancer
60. Prostate cancer detection at low prostate specific antigen
61. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
62. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL
63. Measurement of percent-free PSA improves specifity for lower PSA cutoffs in prostate cancer screening
64. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements
65. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model
66. The appropriate lower limit for the percent free prostate-specific antigen reflex range
67. Ratio free/total PSA (%f-PSA) in men with total PSA 0.5-3 ng/ml: Improvement for prostate cancer detection?
68. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer
69. Association of free PSA percent total PSA age, and gland volume in the detection of prostate cancer
70. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
71. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population
72. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage Tic prostate cancer
73. The use of percent free prostate specific antigen for staging clinically localized prostate cancer
74. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma
75. Serum percent-free PSA does not predict extraprostatic spread of prostate cancer
76. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate
77. Prostate-specific antigen ratio correlates with aggressiveness of histology grades of prostate cancer
78. The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer
79. Prediction of post-radical prostatectomy pathological outcome for stage Tic prostate cancer with free prostate specific antigen: A prospective multicenter clinical trial
80. Diagnostic value of percent free prostate-specific antigen: Retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL
81. Percentage of free prostate-specific anztigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis
82. Clinical evolution of prostatic intraepithelial neoplasia
83. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: Predictive accuracy in needle biopsy
84. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels
85. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
86. Ratio of free to total prostate-specific antigen in patients with prostatic intraepithelial neoplasia
87. Influence of high-grade prostatic intra-epithelial neoplasia on total and percentage free serum prostatic specific antigen
88. Effect of high-grade prostatic intraepithelial neoplasia on total and percent free serum prostatic-specific antigen
89. Ratio of free to total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate
90. Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen
91. Percent of free serum prostate-specific antigen and histological findings in patients undergoing open prostatectomy for benign prostatic hyperplasia
92. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges
93. Free, complexed and total serum prostate specific antigen the establishment of appropriate reference ranges for their concentrations and ratios
94. Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: Age-specific reference ranges for total PSA, free PSA, and percent free PSA
95. The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: Establishment of reference ranges in a large population of healthy men
96. Values for the free to total prostate-specific antigen ratio as a function of age: Necessity of reference range validation
97. Age related changes of free and total prostate specific antigen in serum
98. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen
99. Intraindividual variations of total and percent free serum prostatic-specific antigen levels in patients with normal digital rectal examination
100. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers
101. A prospective study of the serum prostate specific antigen concentrations and Gleason histologie scores of black and white men with prostate carcinoma
102. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men
103. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenter clinical trial
104. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml.
105. Factors influencing the ratio of free to total prostate-specific antigen in serum
106. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia
107. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia
108. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: Which cutoff should be used?
109. Re: 'Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?'
110. The necessity of a second prostate biopsy cannot be predicted by PSA or PSA derivatives (density or free:total ratio) in men with prior negative prostatic biopsies
111. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1051 men
112. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population
113. Adding free to total prostate-specific antigen levels in trials of prostate cancer screening
114. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions
115. Two-year stability of free and total PSA in frozen serum samples
116. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures
117. Preanalytical determinants of total and free prostate-specific antigen and their ratio: Blood collection and storage conditions
118. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia
119. 1-antichymotrypsin from serum
120. Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy
121. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy
122. ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: Proof of new complex forming of PSA after release into circulation
123. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy
124. Effect of digital rectal examination on serum complexed and free prostate-specific antigen and percentage of free prostate-specific antigen
125. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy
126. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting
127. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia
128. Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia
129. Serum prostate specific antigen binding α 1-antichymotrypsin: Influence of cancer volume, location and therapeutic selection of resistant clones
130. Correlation of serum concentrations of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer
131. PSA-ACT immunoassay: Problems and solutions
132. Assay of complexed α 1-antichymotrypsin in plasma
133. Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-α 1-antichymotrypsin complex
134. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background
135. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay
136. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer
137. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: Studies in serum and plasma samples
138. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with α 1-antichymotrypsin
139. Determination of α1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA
140. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer
141. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume
142. α 1-Antichymotrypsin-PSA (ACT-PSA): A useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
143. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum
144. Can complexed PSA be used as a single test for detecting prostate cancer?
145. Measurement of complexed PSA improves specificity for early detection of prostate cancer
146. Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia
147. Complexed prostate specific prostate antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
148. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer
149. Re: 'Complexed prostate specific prostate antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer'
150. Measurement of the complex between prostate-specific antigen and α1-protease inhibitor in serum
151. Addition of purified prostate specific antigen to serum from female subjects: Studies on the relative inhibition by α 2-macroglobulin and α 1-antichymotrypsin
152. Quantitative immunoassay for complexes of prostate-specific antigen with α2-macroglobulin
153. Prostate-specific antigen forms complexes with human α 2-macroglobulin and binds to the α 2-macroglobulin receptor/LDL receptor-related protein
154. Clearance mechanism of prostate specific antigen and its complexes with α2-macroglobulin and α1-antichymotrypsin
155. Report on prostate cancer tumor marker workshop 1999
156. 1-protease inhibitor in vitro
157. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate
158. The new human Kallikrein gone family: Implications in carcinogenesis
159. Human prostate-specific antigen: Structural and functional similarity with serine proteases
160. Primary structure of a human glandular kallikrein gene
161. Characterization of the gone for prostate-specific antigen, a human glandular kallikrein
162. Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene
163. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen
164. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein
165. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation
166. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors
167. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma
168. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors
169. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein
170. The chymotrypsin-like activity of human prostate-specific antigen, γ-seminoprotein
171. Purification of enzymatically active kallikrein hK2 from human seminal plasma
172. α2-Macroglobulin, and C1-inactivator are plasma inhibitors of human glandular kallikrein
173. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1
174. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator
175. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2
176. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2
177. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions
178. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium
179. Kallikrein gene expression in human pituitary tissues
180. Detection of prostate-specific antigen immunoreactivity in breast tumors
181. Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D
182. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids
183. Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid
184. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer
185. Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals
186. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
187. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors
188. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases
189. Decreased concentrations of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) in malignant versus non-malignant prostatic tissue
190. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients
191. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue
192. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2
193. Immunofluommetric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum
194. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic 'gray zone' of total PSA 4 to 10 ng/mL
195. Sensitive and specific irnmunodetection of human glandular kallikrein 2 in serum
196. Development of an ultrasensitive irnmunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen
197. New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease
198. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum
199. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia
200. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
201. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma
202. Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis
203. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA
204. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen
205. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen
206. Human glandular kallikrein 2: A potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer
207. Evaluation of a multivariate prostate-specific antigen and percentage of free prostate-specific antigen logistic regression model in the diagnosis of prostate cancer
208. Estimation of prostate cancer probability by logistic regression: Free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables
209. The development of dual monoclonal antibody immunoassay for accurate measurement of serum human kallikrein 2 complex (chK2)
210. Biochemistry and potential roles of prostatic kallikrein hK2